Dr. Finn on AMG900 in Breast Cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.
AMG900, a small molecule inhibitor of aurora kinases, may have a potential benefit for patients with p53 mutations, Finn says. These mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations.
Finn says these findings suggest that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900. AMG900 is now in a phase I study that includes patients with TNBC. A biomarker component will be included in the study to help researchers get a better understanding of how the drug is working, Finn says.